Literature DB >> 21768661

A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.

P Singh1, J D Wig, R Srinivasan, B D Radotra.   

Abstract

BACKGROUND: Smad4, Smad6 and Smad7 are important molecules in TGF-beta pathway, which plays an important role in pancreatic ductal adenocarcinoma (PDAC) biology. Aims : This study examined the expression profiles of Smad4, Smad6 and Smad7 mRNA in patient samples of PDAC and their relationship to Smad protein expression, SMAD4 gene mutations, clinicopathological parameters and patient survival. SETTINGS AND
DESIGN: Surgically resected, paired normal and tumor tissues of 25 patients of PDAC were studied.
MATERIALS AND METHODS: Protein and mRNA levels were assessed by immunohistochemistry and RT-PCR, respectively. STATISTICAL METHODS: Statistical analysis was done using Student's t-test, Pearson's chi-square test, Spearman's Rank Correlation, Pearson's Correlation test and Kaplan-Meier Logrank test.
RESULTS: While there was a highly significant difference in the protein levels of all three Smads in tumor as compared to normal samples, mRNA levels were significantly different only for Smad4. Protein levels did not correlate significantly with mRNA levels for any of the three Smads. The mRNA levels of Smad4 and Smad6, Smad4 and Smad7, and Smad6 and Smad7 in tumor samples showed a significant positive correlation. The relationship of Smad4 mRNA expression to SMAD4 gene status and Smad4 protein expression was discordant and there was no significant correlation between mRNA expression and clinicopathological parameters and patient survival.
CONCLUSION: The absence of concordance between SMAD4 gene status, mRNA expression and Smad4 protein expression suggests the presence of other regulatory mechanisms in Smad4 transcription and translation in PDAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768661     DOI: 10.4103/0019-509X.82876

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  7 in total

Review 1.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 2.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.

Authors:  Maria Celeste Palmarocchi; Ruben Carlo Balzarotti Canger; Piercarlo Saletti
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

4.  Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-β signaling pathway.

Authors:  Hao Feng; Xiao-Min Jia; Ni-Na Gao; Hua Tang; Wei Huang; Ning Ning
Journal:  Cell Cycle       Date:  2019-09-04       Impact factor: 4.534

5.  Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.

Authors:  David J Birnbaum; Sebastian K S Begg; Pascal Finetti; Charles Vanderburg; Anupriya S Kulkarni; Azfar Neyaz; Thomas Hank; Eric Tai; Vikram Deshpande; François Bertucci; Daniel Birnbaum; Keith D Lillemoe; Andrew L Warshaw; Mari Mino-Kenudson; Carlos Fernandez-Del Castillo; David T Ting; Andrew S Liss
Journal:  Clin Cancer Res       Date:  2021-02-05       Impact factor: 13.801

6.  Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers.

Authors:  Yiping Du; Xin Zhou; Zebo Huang; Tianzhu Qiu; Jian Wang; Wei Zhu; Tongshan Wang; Ping Liu
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

7.  MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells.

Authors:  Jingyi Yu; Rong Lei; Xueqian Zhuang; Xiaoxun Li; Gang Li; Sima Lev; Miguel F Segura; Xue Zhang; Guohong Hu
Journal:  Nat Commun       Date:  2016-12-20       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.